CoChat

Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women

Open access

The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1), an incretin hormone, plays an important role in regulating glucose homeostasis. In this study, the applicability of circulating GLP-1 levels as an early indicator of metabolic syndrome (MetS) risk was examined. Women without diagnosed diseases were grouped according to their number of MetS risk factors (MetS RFs) (no RFs as Super-healthy, n = 61; one or two RFs as MetS risk carriers, n = 60; 3 ≤ RFs as MetS, n = 19). The circulating GLP-1 levels and homeostasis model assessment insulin resistance (HOMA-IR) scores were significantly higher in the MetS group than in the other two groups. The GLP-1 levels correlated positively with adiposity, HOMA-IR, blood pressure, and high sensitivity C-reactive protein (hs-CRP), but not with fasting glucose and lipid profiles, whose significances were maintained after adjustments for age, smoking and drinking habits, menopausal status, and total calorie intake. The GLP-1 levels also increased proportionally with the number of MetS RFs. In the MetS group, the GLP-1 levels were much higher in individuals with obesity (body mass index ≥ 25 kg/m2). In conclusion, the circulating GLP-1 level may be applicable as a potential early indicator of MetS risk in women without diagnosed diseases. Further study with a large population is needed to confirm the conclusion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu13030865

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Circulating glucagon-like peptide-1 (GLP-1) levels and homeostasis model assessment insulin resistance (HOMA-IR) scores in the study participants according to MetS status. Mean ± SD, tested after log transformation of the data; tested by the one-way analysis of variance with the Bonferroni method and with the general linear model after adjustment for confounding factors (age, total calorie intake, cigarette smoking, alcohol drinking, and/or menopausal status); P0: Unadjusted p-value; P1: P-value adjusted for confounding factors. Values sharing the same alphabet indicate no statistically significant differences among them. GLP-1: Glucagon-like peptide-1; HOMA-IR: Homeostatic model assessment of insulin resistance; MetS: Metabolic syndrome.
Figure 1 Circulating glucagon-like peptide-1 (GLP-1) levels and homeostasis model assessment insulin resistance (HOMA-IR) scores in the study participants according to MetS status. Mean ± SD, tested after log transformation of the data; tested by the one-way analysis of variance with the Bonferroni method and with the general linear model after adjustment for confounding factors (age, total calorie intake, cigarette smoking, alcohol drinking, and/or menopausal status); P0: Unadjusted p-value; P1: P-value adjusted for confounding factors. Values sharing the same alphabet indicate no statistically significant differences among them. GLP-1: Glucagon-like peptide-1; HOMA-IR: Homeostatic model assessment of insulin resistance; MetS: Metabolic syndrome.CC BY · PubMed Central
Figure 2 Circulating GLP-1 levels (a) and HOMA-IR scores (b) according to the number of MetS RFs. Mean ± SD, tested after log transformation of the data; tested by the one-way analysis of variance with the Bonferroni method and by the general linear model after adjustment for confounding factors (age, total calorie intake, cigarette smoking, alcohol drinking, and/or menopausal status); P0: Unadjusted p-value, P1: P-value adjusted for confounding factors. Values sharing the same alphabet indicate no statistically significant differences among them. GLP-1: Glucagon-like peptide-1; HOMA-IR: Homeostatic model assessment of insulin resistance; MetS RFs: Metabolic syndrome risk factors. Zero MetS RFs, n = 61; 1 MetS RF, n = 33; 2 MetS RFs, n = 27; 3 MetS RFs, n = 16; 4 MetS RFs, n = 3.
Figure 2 Circulating GLP-1 levels (a) and HOMA-IR scores (b) according to the number of MetS RFs. Mean ± SD, tested after log transformation of the data; tested by the one-way analysis of variance with the Bonferroni method and by the general linear model after adjustment for confounding factors (age, total calorie intake, cigarette smoking, alcohol drinking, and/or menopausal status); P0: Unadjusted p-value, P1: P-value adjusted for confounding factors. Values sharing the same alphabet indicate no statistically significant differences among them. GLP-1: Glucagon-like peptide-1; HOMA-IR: Homeostatic model assessment of insulin resistance; MetS RFs: Metabolic syndrome risk factors. Zero MetS RFs, n = 61; 1 MetS RF, n = 33; 2 MetS RFs, n = 27; 3 MetS RFs, n = 16; 4 MetS RFs, n = 3.CC BY · PubMed Central
Figure 3 Circulating GLP-1 levels (a) and HOMA-IR scores (b) according to the combination of obesity and MetS status. Mean ± SD, tested after log transformation of the data; tested by the one-way analysis of variance with the Bonferroni method and with the general linear model with LSD after adjustment for confounding factors (age, total calorie intake, cigarette smoking, alcohol drinking, and menopausal status); P0: Unadjusted p-value, P1: P-value adjusted for confounding factors. Values sharing the same alphabet indicate no statistically significant differences among them. GLP-1: Glucagon-like peptide-1; HOMA-IR: Homeostatic model assessment of insulin resistance; MetS: Metabolic syndrome. Non-obesity group: Super-healthy, n = 57; MetS risk carriers, n = 31; and MetS, n = 2. Obesity group: Super-healthy, n = 4; MetS risk carriers, n = 29; and MetS, n = 17.
Figure 3 Circulating GLP-1 levels (a) and HOMA-IR scores (b) according to the combination of obesity and MetS status. Mean ± SD, tested after log transformation of the data; tested by the one-way analysis of variance with the Bonferroni method and with the general linear model with LSD after adjustment for confounding factors (age, total calorie intake, cigarette smoking, alcohol drinking, and menopausal status); P0: Unadjusted p-value, P1: P-value adjusted for confounding factors. Values sharing the same alphabet indicate no statistically significant differences among them. GLP-1: Glucagon-like peptide-1; HOMA-IR: Homeostatic model assessment of insulin resistance; MetS: Metabolic syndrome. Non-obesity group: Super-healthy, n = 57; MetS risk carriers, n = 31; and MetS, n = 2. Obesity group: Super-healthy, n = 4; MetS risk carriers, n = 29; and MetS, n = 17.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 21

Metadata

Authors
Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y.
Affiliations
  • Dong-A University (KR)
  • Chonnam National University (KR)
Corresponding author
  • Song, Juhyun
  • Kim, Oh Yoen
Venue
Nutrients
Publisher
MDPI AG
Published
2021-03-06
Volume
13
Issue
3
Pages
865
ISSN
2072-6643 (ISSN-L)
OpenAlex
W3133910378
Cited by
21
References
51
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 2
FWCI
2.99
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (NRF-2019R1F1A1054111, NRF-2016R1A2B4013627 and NRF-2019R1I1A3A01058861)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
glucagon-like peptide-1, metabolic syndrome, metabolic syndrome risk factors, insulin resistance, HOMA-IR, obesity, adiposity, C-reactive protein, blood pressure, women, incretins
MeSH terms
Adult, Blood Glucose, Blood Pressure, C-Reactive Protein, Fasting, Female, Homeostasis, Humans, Insulin, Insulin Resistance, Lipids, Predictive Value of Tests, Biomarkers, Risk Assessment, Metabolic Syndrome, Early Diagnosis, Adiposity, Glucagon-Like Peptide 1, Young Adult, Republic of Korea

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.